



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2023

Physical activity and brain health in patients with atrial fibrillation

Herber, Elena ; Aeschbacher, Stefanie ; Coslovsky, Michael ; Schwendinger, Fabian ; Hennings, Elisa ; Gasser, Andreas ; Di Valentino, Marcello ; Rigamonti, Elia ; Reichlin, Tobias ; Rodondi, Nicolas ; Netzer, Seraina ; Beer, Juerg H ; Stauber, Annina ; Müller, Andreas ; Ammann, Peter ; Sinnecker, Tim ; Duering, Marco ; Wuerfel, Jens ; Conen, David ; Kühne, Michael ; Osswald, Stefan ; Bonati, Leo H

DOI: <https://doi.org/10.1111/ene.15660>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-258355>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.




Originally published at:

Herber, Elena; Aeschbacher, Stefanie; Coslovsky, Michael; Schwendinger, Fabian; Hennings, Elisa; Gasser, Andreas; Di Valentino, Marcello; Rigamonti, Elia; Reichlin, Tobias; Rodondi, Nicolas; Netzer, Seraina; Beer, Juerg H; Stauber, Annina; Müller, Andreas; Ammann, Peter; Sinnecker, Tim; Duering, Marco; Wuerfel, Jens; Conen, David; Kühne, Michael; Osswald, Stefan; Bonati, Leo H (2023). Physical activity and brain health in patients with atrial fibrillation. *European Journal of Neurology*, 30(3):567-577.

DOI: <https://doi.org/10.1111/ene.15660>

ORIGINAL ARTICLE

Physical activity and brain health in patients with atrial fibrillation

Elena Herber^{1,2}  | Stefanie Aeschbacher^{1,2} | Michael Coslovsky^{1,2,3} | Fabian Schwendinger⁴ | Elisa Hennings^{1,2} | Andreas Gasser¹ | Marcello Di Valentino⁵ | Elia Rigamonti⁶ | Tobias Reichlin⁷ | Nicolas Rodondi^{8,9} | Seraina Netzer^{8,9} | Juerg H. Beer¹⁰ | Annina Stauber¹¹ | Andreas Müller¹¹ | Peter Ammann¹² | Tim Sinnecker¹³  | Marco Duering¹³ | Jens Wuerfel^{13,14} | David Conen¹⁵ | Michael Kühne^{1,2} | Stefan Osswald^{1,2}  | Leo H. Bonati^{16,17} | for the SWISS-AF Investigators[†]

¹Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland

²Cardiology Division, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland

³Clinical Trial Unit Basel, Department of Clinical Research, University Hospital Basel, Basel, Switzerland

⁴Division of Sports and Exercise Medicine, Department of Sport, Exercise, and Health, University Basel, Basel, Switzerland

⁵Department of Cardiology, San Giovanni Hospital, Bellinzona, Switzerland

⁶Department of Internal Medicine, Cantonal Hospital Authority, Lugano, Switzerland

⁷Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁸Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

⁹Institute of Primary Health Care, University of Bern, Bern, Switzerland

¹⁰Department of Medicine, Cantonal Hospital of Baden and Molecular Cardiology, University Hospital of Zurich, Zurich, Switzerland

¹¹Department of Cardiology, Triemli Hospital Zurich, Zurich, Switzerland

¹²Department of Cardiology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland

¹³Medical Image Analysis Center and Department of Biomedical Engineering, University of Basel, Basel, Switzerland

¹⁴Department of Radiology, University Hospital Magdeburg, Magdeburg, Germany

¹⁵Population Health Research Institute, McMaster University, Hamilton, Canada

¹⁶Department of Neurology and Stroke Center, University Hospital Basel, University of Basel, Basel, Switzerland

¹⁷Research Department, Reha Rheinfelden, Rheinfelden, Switzerland

Correspondence

Leo H. Bonati, Reha Rheinfelden, Salinenstrasse 98, Rheinfelden CH-4310, Switzerland.
Email: l.bonati@reha-rhf.ch

Funding information

Foundation for Cardiovascular Research Basel (FCVR); Schweizerische Herzstiftung; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung,

Abstract

Background and purpose: Vascular brain lesions, such as ischemic infarcts, are common among patients with atrial fibrillation (AF) and are associated with impaired cognitive function. The role of physical activity (PA) in the prevalence of brain lesions and cognition in AF has not been investigated.

Methods: Patients from the multicenter Swiss-AF cohort study were included in this cross-sectional analysis. We assessed regular exercise (RE; at least once weekly) and minutes of weekly PA using a validated questionnaire. We studied associations with ischemic

[†]All Swiss-AF investigators are listed in the supplement.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Grant/Award Number: 32003B_197524, 32473B_176178, 33CS30_177520 and numbers 33CS30_148474; Universität Basel

infarcts, white matter hyperintensities, cerebral microbleeds, and brain volume on brain magnetic resonance imaging and with global cognition measured with a cognitive construct (CoCo) score.

Results: Among 1490 participants (mean age = 72 ± 9 years), 730 (49%) engaged in RE. In adjusted regression analyses, RE was associated with a lower prevalence of ischemic infarcts (odds ratio [OR] = 0.78, 95% confidence interval [CI] = 0.63–0.98, $p = 0.03$) and of moderate to severe white matter hyperintensities (OR = 0.78, 95% CI = 0.62–0.99, $p = 0.04$), higher brain volume (β -coefficient = 10.73, 95% CI = 2.37–19.09, $p = 0.01$), and higher CoCo score (β -coefficient = 0.08, 95% CI = 0.03–0.12, $p < 0.001$). Increasing weekly PA was associated with higher brain volume (β -coefficient = 1.40, 95% CI = 0.65–2.15, $p < 0.001$).

Conclusions: In AF patients, RE was associated with a lower prevalence of ischemic infarcts and of moderate to severe white matter disease, with larger brain volume, and with better cognitive performance. Prospective studies are needed to investigate whether these associations are causal. Until then, our findings suggest that patients with AF should be encouraged to remain physically active.

KEYWORDS

atrial fibrillation, cerebral infarction, cerebral microbleeds, cognitive disorders and dementia, neurocognitive function, physical activity, total brain volume, white matter disease

INTRODUCTION

The prevalence and incidence of atrial fibrillation (AF) is increasing globally [1, 2]. Lifetime risk of AF was one in three among White women and men in the Atherosclerosis Risk in Communities cohort in the United States and one in five among African Americans [3].

Cognitive impairment is a global health concern, and emerging evidence indicates that AF is associated with cognitive decline and dementia [4–6]. The increased risk of stroke in AF patients partially explains this association, but covert brain infarcts and other mechanisms may cause cognitive impairment among AF patients without a history of clinically manifest stroke [5–7]. Covert brain lesions may be of cardioembolic origin, but may also occur due to concomitant large artery or small vessel disease owing to shared vascular risk factors.

Treatment of covert brain lesions such as white matter hyperintensities (WMHs) of presumed vascular origin is currently limited to preventive lifestyle modifications and risk factor management [8]. In previous studies, physical activity (PA) was reported to be associated with reduced risk of coronary heart disease, ischemic stroke, and total cardiovascular disease in older adults [9]. Accordingly, increasing PA in late life is assumed to promote cerebral small vein integrity [10]. Physical inactivity has been associated with increased risk for dementia in older individuals [11] and poor performance on neurocognitive tests [12]. Regular leisure time PA, on the other hand, has been associated with reduced risk of dementia or Alzheimer disease in longitudinal studies [13, 14]. Additionally, PA has been associated with a larger brain volume in older adults [15]. However, a number of studies have not been able to confirm an association between PA and brain volume, WMH volume, or hippocampal volume [16–18]. Whether PA may have a beneficial effect on covert brain lesions and

cognitive performance in patients with AF has yet to be explored. The aim of the present study was to investigate the association between PA and vascular brain lesions, brain volume, and cognition in an elderly Swiss cohort of AF patients.

METHODS

Study design and patient population

This was a cross-sectional analysis of patients participating in the Swiss-AF study (Swiss Atrial Fibrillation Cohort; [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02105844) identifier: NCT02105844), an ongoing, prospective, multicentric study in Switzerland, including German-, French-, and Italian-speaking regions. One of the main aims of Swiss-AF is to investigate the association of AF with cognitive decline and dementia [19]. A total of 2415 patients with documented AF aged ≥ 65 years, including a subgroup of approximately 10% of patients aged < 65 years to assess socioeconomic aspects, were recruited between 2014 and 2017. Exclusion criteria were the inability to provide informed consent, exclusively nonsustained episodes of AF due to reversible causes, or any acute illness (including stroke or transient ischemic attack [TIA]) within 4 weeks before inclusion.

Standard protocol approvals, registrations, and patient consents

The study protocol adheres to the Declaration of Helsinki and has been approved by the local ethics committee EKNZ (Ethikkommission

Nordwest- und Zentralschweiz). Written informed consent was signed by each participant.

Data acquisition

Questionnaires were used to assess demographic information, including age, sex, and education level. Education levels were classified as basic (≤ 6 years), middle (> 6 years and ≤ 12 years), and advanced (> 12 years of education). Weight and height were asked to determine body mass index (kg/m^2). Smoking status was classified as active, past, or never. Alcohol intake was assessed as average drinks per day. A self-perception score from 0 to 100 was used to assess the patients' current impression concerning their overall state of health. Zero represents the worst, and 100 represents the best imaginable state of health. Medical history, risk factors, and medication including anticoagulation were asked to evaluate medical conditions. The CHA₂DS₂-VASc score was calculated subsequently. The AF type was divided into paroxysmal (self-terminating, < 7 days), persistent (≥ 7 days and/or requiring cardioversion), and permanent AF (unsuccessful cardioversion or no attempt to terminate AF). Blood pressure was measured in supine position at study enrollment [19].

Assessment of exercise and physical activity

Physical activity was assessed by questionnaires, first asking whether participants engaged in regular physical exercise, listing jogging, Nordic walking, cycling, aerobics, or ball sports as examples. Regular exercise (RE) was defined as performing such activities at least once per week. The choice of this cutoff was arbitrary and informed by the distribution of PA in our study population, yielding patient groups of comparable size.

The quantity and intensity of weekly PA were reported using the validated International Physical Activity Questionnaire (IPAQ) [20, 21], which assesses the amount of weekly "vigorous" (making one breathe much harder than normal) and "moderate" (making one breathe somewhat harder than normal) PA, as well as walking (including any walking, at work, at home, or during leisure time). As a quantitative measure of weekly PA, we calculated the metabolic equivalent of task (MET)-minutes per week as an index of energy expenditure based on the information gathered with the IPAQ (MET-min/week). Additionally, we adapted the MET intensity by age according to the American College of Sports Medicine (MET-min/week age adapted) [22]. For middle-aged participants (40–64 years old), the following factors as mean of the corresponding range were used: walking = 2.95 METs, moderate intensity = 4.95 METs, vigorous intensity = 7.2 METs. For older participants (≥ 65 years old), walking = 2.35 METs, moderate intensity = 3.95 METs, and vigorous intensity = 5.75 METs were used. The reason for using age-adapted MET values was recent evidence showing that absolute intensity cutoffs may lead to false classification of PA in populations other than those the cutoffs were derived from [23].

Brain magnetic resonance imaging and brain lesions

A standardized brain magnetic resonance imaging (bMRI) protocol without contrast agent was run in AF patients without contraindications (cardiac device, claustrophobia). Images were evaluated by trained neuroradiologists at the Medical Image Analysis Center in Basel. MRIs were assessed without knowledge of the patients' PA. The following lesions were discerned, as previously described [6]. Large noncortical and cortical infarcts (LNCCIs) included cortical infarcts defined as hyperintense lesions on fluid-attenuated inversion recovery (FLAIR) involving the cortex irrespective of their size and whether they also involve subcortical areas and noncortical lesions with a diameter > 20 mm [6]. Small noncortical infarcts (SNCCIs) consist of hyperintense lesions on FLAIR of ≤ 20 mm in diameter on axial sections not involving the cortex, consistent with ischemic infarction in the territory of a perforating arteriole (located in the white matter, internal or external capsule, deep brain nuclei, thalamus, or brainstem) [6]. For this specific analysis, we combined the prevalence and volume of LNCCIs and SNCCIs and analyzed them together as any ischemic infarct. WMHs [24] of presumed vascular origin were identified and graded on FLAIR images using the Fazekas scale. Moderate to severe WMH was defined as a score ≥ 2 in either the periventricular or the deep white matter region. Cerebral microbleeds (CMBs) [24] were identified as round, small (generally 2–5 mm in diameter, but sometimes up to 10 mm) areas of signal void with associated blooming seen on T2*-weighted MRI or other sequences that are sensitive to susceptibility effects [6]. The normalized brain volume (nBV) was estimated in milliliters on three-dimensional T1-weighted magnetization-prepared rapid acquisition gradient echo images using SIENAX and normalized for skull size [25].

Neurocognitive function

The following neurocognitive tests were performed by trained study personnel in a standardized manner according to the study protocol. Montreal cognitive assessment (MoCA) evaluates memory, visuospatial abilities, executive functions, phonemic fluency, attention, concentration, confrontation naming, abstraction, and orientation [26]. Trail Making Test (TMT) assesses visual attention, processing speed, and executive functions. The test consists of connecting numbers in ascending order (TMT-A) and connecting numbers and letters alternating in ascending or alphabetic order, respectively (TMT-B) [27]. Semantic Fluency Test (SFT) tests for semantic memory and language production, for which patients are asked to name as many animals as possible within 1 min [28]. Digit Symbol Substitution Test (DSST) explores cognitive aspects such as information processing speed, visuomotor coordination, and attention [19]. The cognitive construct (CoCo) score is a score previously derived from the individual components of all neurocognitive tests performed in Swiss-AF (MoCA, TMT, SFT, DSST) using latent factor analysis and summarizes global cognitive performance [29].

TABLE 1 Baseline characteristics overall and stratified by regular exercise

Characteristic	Overall	Regular exercise		p
		Yes	No	
n (%)	1490	730 (49.0)	760 (51.0)	
Age, years, mean (SD)	72.3 (8.5)	71.5 (8.0)	73.2 (8.9)	<0.001
Female sex, n (%)	392 (26.3)	189 (25.9)	203 (26.7)	0.76
Education level, n (%)				
Basic	162 (10.9)	55 (7.5)	107 (14.1)	<0.001
Middle	739 (49.6)	329 (45.1)	410 (53.9)	
Advanced	588 (39.5)	345 (47.3)	243 (32.0)	
Body mass index, kg/m ² , mean (SD)	27.6 (4.7)	27.1 (4.3)	28.1 (4.9)	<0.001
Blood pressure, systolic/diastolic, mmHg, mean (SD)	134/78 (19/12)	134/79 (18/11)	135/77 (19/13)	0.90/0.002
Smoking status, n (%)				
Active	112 (7.5)	45 (6.2)	67 (8.8)	0.007
Past	724 (48.6)	337 (46.2)	387 (50.9)	
Never	654 (43.9)	348 (47.7)	306 (40.3)	
Average alcohol intake, drinks/day, median [IQR]	0.50 [0.1, 1.3]	0.57 [0.1, 1.3]	0.50 [0.1, 1.3]	0.04
Health perception score (0–100), median [IQR]	80.0 [65.0, 85.0]	80.0 [70.0, 90.0]	74.5 [60.0, 80.0]	<0.001
Atrial fibrillation type, n (%)				
Paroxysmal	690 (46.3)	342 (46.8)	348 (45.8)	0.11
Persistent	461 (30.9)	238 (32.6)	223 (29.3)	
Permanent	339 (22.8)	150 (20.5)	189 (24.9)	
CHA ₂ DS ₂ -VAsc score, mean (SD)	3.2 (1.7)	3.0 (1.7)	3.4 (1.8)	<0.001
Medical history, n (%)				
Diabetes	212 (14.2)	70 (9.6)	142 (18.7)	<0.001
Hypertension	1016 (68.2)	468 (64.1)	548 (72.1)	0.001
Heart failure	318 (21.4)	130 (17.8)	188 (24.8)	0.001
Coronary artery disease	411 (27.6)	195 (26.7)	216 (28.4)	0.50
Clinical stroke	186 (12.5)	84 (11.5)	102 (13.4)	0.30
TIA	135 (9.1)	58 (7.9)	77 (10.1)	0.17
Major bleeding	79 (5.3)	29 (4.0)	50 (6.6)	0.03
Renal failure	263 (17.7)	121 (16.6)	142 (18.7)	0.32
Cardiovascular medication, n (%)				
Antihypertensive drugs ^a	1301 (87.3)	606 (83.0)	695 (91.4)	<0.001
Beta blockers	1027 (68.9)	489 (67.0)	538 (70.8)	0.13
ACE inhibitors	439 (29.5)	199 (27.3)	240 (31.6)	0.08
Angiotensin receptor blockers	453 (30.4)	219 (30.0)	234 (30.8)	0.78
Digoxin	72 (4.8)	32 (4.4)	40 (5.3)	0.50
Diuretics	618 (41.5)	248 (34.0)	370 (48.7)	<0.001
Statin therapy [hypercholesterolemia]	714 (47.9)	332 (45.5)	382 (50.3)	0.07
Antiarrhythmics, Class Ic and III	312 (20.9)	144 (19.7)	168 (22.1)	0.29
Oral anticoagulation intake, n (%)	1339 (89.9)	659 (90.3)	680 (89.5)	0.67
NOAC	788 (52.9)	395 (54.1)	393 (51.7)	0.38
Vitamin K antagonist	551 (37.0)	264 (36.2)	287 (37.8)	0.56
Antiplatelet therapy, including aspirin	268 (18.0)	117 (16.0)	151 (19.9)	0.06
Physical activity, MET-min/week [IQR]	4479 [1780, 8943]	5466 [2772, 9583]	3193 [1342, 7899]	<0.001
Physical activity, MET-min/week, age-adapted, median [IQR]	3633 [1418, 7266]	4343 [2195, 7862]	2540 [987, 6389]	<0.001

Note: Values are presented as mean ± SD, median (interquartile range) or n (%). Education levels were defined as basic, ≤6 years; middle, >6 years and ≤12 years; and advanced, >12 years of education. CHA₂DS₂-VAsc score = heart failure, hypertension, age ≥ 75 years (2 points), diabetes, history of stroke, TIA, or thromboembolism (2 points), vascular disease, age ≥ 65 and < 75 years, female sex. Health perception score is a self-assessment concerning the participants' current state of health on a scale from 0 to 100.

Missing values: blood pressure (n = 6), heart failure (n = 1), renal failure (n = 1), education level (n = 1).

Abbreviations: ACE, angiotensin-converting enzyme; IQR, interquartile range; MET, metabolic equivalent of task; NOAC, new oral anticoagulants; TIA, transient ischemic attack.

^aAntihypertensive drugs include ACE inhibitors, beta blockers, angiotensin-1 receptor blockers, calcium antagonists, diuretics, renin antagonists, and aldosterone antagonists.

TABLE 2 Prevalence and volume of brain lesions detected on brain magnetic resonance imaging stratified by regular exercise

All patients, <i>n</i> = 1490	Overall	Regular exercise	
		Yes	No
Any ischemic infarct, LNCCI and SNCI			
Prevalence, <i>n</i> (%)	561 (37.7)	244 (33.4)	317 (41.7)
Volume, mm ³ , median [IQR]	285 [69, 2361]	279 [66, 3317]	288 [75, 2223]
CMBs			
Prevalence, <i>n</i> (%)	314 (21.7)	136 (19.3)	178 (24.1)
Counts, median [IQR]	1.0 [1.0, 2.0]	1.0 [1.0, 2.0]	1.0 [1.0, 2.0]
WMHs			
Prevalence, Fazekas scale ≥ 2 , <i>n</i> (%)	784 (52.7)	347 (47.5)	437 (57.6)
Volume, mm ³ , median [IQR]	3756 [1368, 9480]	3177 [1242, 7830]	4172 [1562, 10,803]

Note: Values are median [IQR] or *n* (%). Only the volume of patients showing presence of lesions was taken into account. Missing values: CMB count (*n* = 46), WMHs (*n* = 1).

Abbreviations: CMB, cerebral microbleed; IQR, interquartile range; LNCCI, large noncortical and cortical infarcts (including acute lesions); SNCI, small noncortical infarcts (including acute lesions); WMH, white matter hyperintensity.

Statistical analysis

The baseline characteristics were displayed overall and stratified by RE (yes or no). Continuous variables are presented as mean \pm SD or median (interquartile range [IQR]), as appropriate. Categorical data are presented as absolute and relative frequencies.

The associations between RE as a binary variable and the prevalence of ischemic infarcts, CMBs, and moderate to severe WMHs as outcome variables were investigated with multivariate adjusted logistic regression models. We used multivariate adjusted linear regression models to evaluate the association of RE with total brain




FIGURE 1 Prevalence (%) of vascular brain lesions stratified by regular exercise (RE). The bar chart shows the prevalence of ischemic infarcts, microbleeds, and white matter disease as relative frequencies (percentages) and stratified by RE. Probability values are adjusted for age, sex, smoking status, atrial fibrillation type (paroxysmal vs. nonparoxysmal), hypertension, diabetes mellitus, heart failure, coronary heart disease, statin therapy, antihypertensive medication, oral anticoagulation, and antiplatelet therapy. PA, physical activity

volume and cognition. Age-adapted MET-min/week was used as a quantitative measure of PA, both as a continuous variable (per 1000 MET-min/week) and as a categorical variable using quartiles. The *p*-value for linear trend was calculated to describe the shape of the association. Results are presented as odds ratios (ORs) or β -coefficients, 95% confidence intervals (CIs), and *p*-values, with a *p*-value <0.05 indicating statistical significance.

Various adjustments were done. Model 1 was unadjusted, Model 2 was adjusted for age and sex, and Model 3 was additionally adjusted for smoking status, AF type (paroxysmal vs. nonparoxysmal), hypertension, diabetes mellitus, heart failure, coronary heart disease, statin therapy, antihypertensive medication, oral anticoagulation, and antiplatelet therapy. In addition to these variables, the regression analysis using neurocognitive function as the outcome was adjusted for education (Models 1–3) and for the presence of ischemic infarcts or moderate to severe WMHs ≥ 2 (Model 3). As a sensitivity analysis, all analyses were repeated excluding patients with a history of stroke or TIA. Additionally, the CoCo score stratified by RE was calculated for the following age strata: ≤ 60 , 61–70, 71–80, >80 years. To assess how well the results from this analytic sample apply to the complete study sample, we compared the baseline characteristics of included Swiss-AF patients with those who were excluded from the present analysis. The statistical analysis was performed using R (version 4.1.0).

RESULTS

A total of 1490 patients with bMRI, and available data on PA and neurocognitive function were included (Figure S1). The most common reason for exclusion was lack of bMRI. Mean age was 72 ± 9 years, and 392 patients (26%) were female. Most patients had paroxysmal AF (690, 46%), 461 patients (31%) had persistent AF,

TABLE 3 Association of regular exercise and weekly physical activity with the prevalence of brain lesions

All patients, <i>n</i> = 1490	Model 1	Model 2	Model 3
	OR (95% CI), <i>p</i>	OR (95% CI), <i>p</i>	OR (95% CI), <i>p</i>
Any ischemic infarct			
Regular exercise, yes/no	0.70 (0.57–0.87), <0.001	0.77 (0.62–0.96), 0.02	0.78 (0.63–0.98), 0.03
Physical activity, per 1000 MET-min/week	0.97 (0.95–0.99), 0.003	0.99 (0.97–1.01), 0.48	0.99 (0.97–1.01), 0.52
Q1: <1417 MET-min/week	Ref	Ref	Ref
Q2: 1417–3634 MET-min/week	0.87 (0.65–1.16), 0.33	0.89 (0.66–1.20), 0.44	0.88 (0.65–1.20), 0.43
Q3: 3635–7265 MET-min/week	0.79 (0.59–1.06), 0.12	0.83 (0.61–1.13), 0.24	0.82 (0.60–1.11), 0.20
Q4: >7265 MET-min/week	0.63 (0.47–0.85), 0.002	0.80 (0.59–1.10), 0.17	0.81 (0.59–1.11), 0.20
<i>p</i> for linear trend	0.002	0.16	0.17
Cerebral microbleeds			
Regular exercise, yes/no	0.76 (0.59–0.97), 0.03	0.82 (0.63–1.06), 0.13	0.86 (0.66–1.11), 0.24
Physical activity, per 1000 MET-min/week	0.94 (0.91–0.96), <0.001	0.95 (0.92–0.98), <0.001	0.95 (0.92–0.98), <0.001
Q1: <1417 MET-min/week	Ref	Ref	Ref
Q2: 1417–3634 MET-min/week	0.99 (0.71–1.38), 0.93	1.00 (0.72–1.41), 0.98	1.04 (0.74–1.46), 0.84
Q3: 3635–7265 MET-min/week	0.87 (0.62–1.22), 0.42	0.89 (0.63–1.26), 0.51	0.90 (0.63–1.28), 0.56
Q4: >7265 MET-min/week	0.44 (0.30–0.65), <0.001	0.53 (0.35–0.78), 0.001	0.54 (0.36–0.81), 0.003
<i>p</i> for linear trend	<0.001	0.001	0.002
White matter hyperintensities, Fazekas scale ≥ 2			
Regular exercise, yes/no	0.67 (0.54–0.82), <0.001	0.76 (0.61–0.95), 0.02	0.78 (0.62–0.99), 0.04
Physical activity, per 1000 MET-min/week	0.97 (0.95–0.99), <0.001	1.01 (0.99–1.03), 0.39	1.01 (0.99–1.03), 0.45
Q1: <1417 MET-min/week	Ref	Ref	Ref
Q2: 1417–3634 MET-min/week	0.95 (0.71–1.26), 0.71	1.04 (0.76–1.43), 0.81	1.06 (0.77–1.46), 0.73
Q3: 3635–7265 MET-min/week	0.82 (0.61–1.09), 0.17	0.90 (0.66–1.24), 0.53	0.90 (0.65–1.25), 0.53
Q4: >7265 MET-min/week	0.72 (0.54–0.96), 0.03	1.16 (0.84–1.60), 0.38	1.16 (0.84–1.62), 0.37
<i>p</i> for linear trend	0.01	0.57	0.58

Note: Physical activity: MET-min/week was calculated from the International Physical Activity Questionnaire and age-adapted according to the American College of Sports Medicine [22].

Model 1: univariable; Model 2: adjusted for age and sex; Model 3: additionally adjusted for smoking status, atrial fibrillation type (paroxysmal vs. nonparoxysmal), hypertension, diabetes mellitus, heart failure, coronary heart disease, statin therapy, antihypertensive medication, oral anticoagulation, and antiplatelet therapy.

Missing values: cerebral microbleeds (*n* = 46), white matter hyperintensities (*n* = 1), heart failure (*n* = 1).

Abbreviations: CI, confidence interval; MET, metabolic equivalent of task; OR, odds ratio; Q, quartile; Ref, reference.

and 339 (23%) had permanent AF. Almost half of the participants reported engaging in RE (730, 49%). Patients doing RE achieved a median of 4343 age-adapted MET-min/week (IQR = 2195–7862), whereas patients without RE activities achieved a median of 2540 age-adapted MET-min/week (IQR = 987–6389). Patients doing RE were younger and tended to have fewer cardiovascular risk factors such as diabetes or hypertension, less cardiovascular medication, and higher education than those who did not report RE (Table 1). The mean CHA₂DS₂-VASc score of the entire analysis population was 3.2 ± 1.7.

Participants in Swiss-AF who were excluded from this analysis were older (74.4 vs. 72.3 years) and had more medical risk factors (CHA₂DS₂-VASc score = 3.8 vs. 3.2), more cardiovascular medication, lower health perception scores, and less PA than the patients

included in this analysis. The differences in patient characteristics according to RE were similar to the included patients (Table S4).

Table 2 presents the prevalence and volume of vascular brain lesions on MRI stratified by RE. Overall, patients reporting RE less often had ischemic infarcts (244 [33%] vs. 317 [42%]), CMBs (136 [19%] vs. 178 [24%]), and moderate to severe WMHs (347 [48%] vs. 437 [58%]) than those not engaging in RE (Figure 1).

Table 3 shows the association of RE and weekly PA (quantified in MET-min/week) with the presence of vascular brain lesions on MRI in all three models. Patients engaging in RE had significantly lower odds of having ischemic infarcts (OR = 0.78, 95% CI = 0.63–0.98, *p* = 0.03) and moderate to severe WMHs (OR = 0.78, 95% CI = 0.62–0.99, *p* = 0.04), even after adjustment for cardiovascular risk factors (Model 3). There was no association between RE and the presence




FIGURE 2 Total brain volume (ml) and cognitive construct (CoCo) score stratified by regular exercise (RE). The violin plot shows the distribution of (a) total brain volume (RE yes: median = 1430 ml, interquartile range [IQR] = 1365–1493; RE no: median = 1400 ml, IQR = 1347–1466) and (b) CoCo score (RE yes: median = 0.14, IQR = −0.19–0.48; RE no: median = −0.09, IQR = −0.43 to 0.30) compared between Swiss-AF participants doing RE or not. The box illustrates the range between the first and third quartile, the median is shown as a line splitting the box, and the cross indicates the mean

of CMBs. Weekly PA was inversely associated with the presence of CMBs (Model 3; OR = 0.95, 95% CI = 0.92–0.98, $p < 0.001$ per 1000 MET-min/week). This association followed a linear trend (p for linear trend = 0.002). There were no significant associations between weekly PA and the presence of ischemic infarcts and moderate to severe WMH in the adjusted logistic regression models (Models 2 and 3).

The sensitivity analysis excluding patients with history of stroke or TIA is shown in Table S2 ($n = 1204$) and showed consistent results compared to the main analysis.

Both total brain volume (median = 1430 ml [IQR = 1365–1493] vs. 1400 ml [IQR = 1347–1466]) and global cognitive performance CoCo score (median = 0.14 [IQR = −0.19 to 0.48] vs. −0.09 [IQR = −0.43 to 0.30]) were higher in patients reporting RE (Figure 2). The CoCo score was higher among patients reporting RE in each age stratum (Figure S2).

Table 4 shows the association of RE and PA with total brain volume and cognitive function. RE and weekly PA were strongly associated with nBV. Weekly MET-min followed a linear trend showing more activity was associated with higher brain volume (p for linear trend < 0.001). Patients reporting RE had significantly higher CoCo scores, also when adjusted for education, cardiovascular risk factors, and the presence of brain infarcts (Model 3; β -coefficient = 0.08, 95% CI = 0.03–0.12, $p < 0.001$).

DISCUSSION

This cross-sectional analysis revealed several potentially important findings on PA and brain health in patients with AF. First, patients engaging in RE less often had ischemic brain infarcts or moderate to severe white matter disease on MRI. Second, higher intensity and quantity of PA was inversely associated with the prevalence of CMBs. Third, patients engaging in RE and who were physically more active had larger nBVs. Fourth, patients reporting RE performed better on cognitive tests.

From a physiological perspective, exercise may promote "brain health" by altering mechanisms of neuronal plasticity and supporting the brain's structural integrity and function [30]. Neuroprotective mechanisms of exercise can be explained with improved cerebrovascular angiogenesis and neurogenesis, reduced neuronal apoptosis, altered inflammatory response, and higher antioxidant capacity [30, 31]. Higher antioxidant capacity leads to an increased ischemic tolerance of brain tissue [31]. Previous small studies demonstrated that PA was associated with a lower burden of neuroimaging lesions of presumed vascular origin in older adults [10]. Covert brain infarcts are common among patients with AF [4, 6], but the evidence regarding to what extent patients with AF might benefit from PA has been limited. Escudero-Martínez et al. found that a high level of PA combined with good adherence to a Mediterranean diet was associated with a lower risk of silent brain infarcts in patients with AF [32]. No independent association of PA and risk reduction of silent brain infarcts was found, but this may have been due to the relatively small sample size of 443 patients and lack of power [32]. We were conscious of potential confounding by reverse causation, as patients who have suffered a stroke are both less able to engage in physical activities and more likely to have brain infarcts on MRI. Therefore, we performed a sensitivity analysis excluding patients with a history of stroke or TIA and found essentially the same effect of PA on covert brain infarcts, in line with previous studies in the general population [9, 31, 33].

We combined brain infarcts of possible embolic origin (LNCCIs) and those presumably caused by small vessel disease in our analysis, chiefly for reasons of power. Thus, we cannot speculate about possible mechanisms by which PA might prevent cerebral infarcts in patients with AF. Of note, the association persisted after adjustment for numerous vascular risk factors, suggesting that the protective effect of PA is at least in part independent of those.

TABLE 4 Association of regular exercise and weekly physical activity with total brain volume and cognitive function

All patients, <i>n</i> = 1490	Model 1	Model 2	Model 3
	β (95% CI), <i>p</i>	β (95% CI), <i>p</i>	β (95% CI), <i>p</i>
Normalized brain volume, ml			
Regular exercise, yes/no	23.43 (13.81 to 33.04), <0.001	14.43 (6.05 to 22.80), <0.001	10.73 (2.37 to 19.09), 0.01
Physical activity, per 1000 MET-min/week	3.41 (2.58 to 4.25), <0.001	1.39 (0.63 to 2.15), <0.001	1.40 (0.65 to 2.15), <0.001
Q1: <1417 MET-min/week	Ref	Ref	Ref
Q2: 1417–3634 MET-min/week	26.50 (13.06 to 39.95), <0.001	24.45 (12.69 to 36.20), <0.001	21.76 (10.18 to 33.34), <0.001
Q3: 3635–7265 MET-min/week	26.49 (13.02 to 39.96), <0.001	21.46 (9.69 to 33.23), <0.001	18.69 (7.08 to 30.31), 0.002
Q4: >7265 MET-min/week	51.48 (38.04 to 64.91), <0.001	28.47 (16.53 to 40.40), <0.001	25.75 (13.96 to 37.54), <0.001
<i>p</i> for linear trend	<0.001	<0.001	<0.001
CoCo			
Regular exercise, yes/no	0.10 (0.05 to 0.14), <0.001	0.09 (0.04 to 0.13), <0.001	0.08 (0.03 to 0.12), <0.001
Physical activity, per 1000 MET-min/week	−0.004 (−0.01 to 0.00), 0.08	−0.004 (−0.01 to 0.00), 0.07	−0.004 (−0.01 to 0.00), 0.06
Q1: <1417 MET-min/week	Ref	Ref	Ref
Q2: 1417–3634 MET-min/week	0.03 (−0.03 to 0.09), 0.30	0.02 (−0.03 to 0.09), 0.39	0.02 (−0.04 to 0.08), 0.44
Q3: 3635–7265 MET-min/week	0.04 (−0.02 to 0.10), 0.18	0.04 (−0.02 to 0.10), 0.22	0.03 (−0.03 to 0.09), 0.28
Q4: >7265 MET-min/week	0.001 (−0.06 to 0.06), 0.98	−0.007 (−0.07 to 0.05), 0.83	−0.01 (−0.07 to 0.05), 0.70
<i>p</i> for linear trend	0.90	0.93	0.79

Note: Physical activity: MET-min/week was calculated from the International Physical Activity Questionnaire and age-adapted according to the American College of Sports Medicine [22]. Normalized brain volume: Model 1 is univariable; Model 2: adjusted for age and sex; Model 3: additionally adjusted for smoking status, atrial fibrillation type (paroxysmal vs. nonparoxysmal), hypertension, diabetes mellitus, heart failure, coronary heart disease, statin therapy, antihypertensive medication, oral anticoagulation, and antiplatelet therapy. CoCo: Model 1 is adjusted for age, sex, and education; Model 2: additionally adjusted for smoking status, atrial fibrillation type (paroxysmal vs. nonparoxysmal), hypertension, diabetes mellitus, heart failure, coronary heart disease, statin therapy, antihypertensive medication, oral anticoagulation, and antiplatelet therapy; Model 3: additionally adjusted for presence of ischemic infarct or moderate to severe white matter disease on brain magnetic resonance imaging. Missing values: white matter hyperintensities (*n* = 1), heart failure (*n* = 1).

Abbreviations: CI, confidence interval; CoCo, cognitive construct; MET, metabolic equivalent of task; Q, quartile; Ref, reference.

WMHs and CMBs are generally considered markers of cerebral small vessel disease [24, 34]. WMHs are associated with an increased risk of stroke, cognitive impairment, and vascular dementia [6, 35]. Among patients with cerebral small vessel disease, PA has been associated with a lower all-cause mortality and lower incidence of cerebrovascular events, although no correlation with WMHs or CMBs was found [36]. Resistance training has been reported to reduce WMH progression in a randomized controlled trial [37]. In a systematic review, higher levels of PA were associated with greater white matter volumes, reduced volume or severity of WMHs, or improved measures of white matter microstructure [18]. Our study expanded these findings to patients with AF by demonstrating a lower prevalence of moderate to severe WMHs among patients engaging in RE, after adjustment for vascular risk factors.

Patients with CMBs are at increased risk for intracranial hemorrhage, which is especially relevant for patients requiring long-term anticoagulation [38, 39]. Our findings relating to the effect of PA on CMBs were less conclusive; although RE was associated with a lower likelihood of CMBs, the association was weakened after adjustment for vascular risk factors. In contrast, weekly PA quantified

by MET-min showed an inverse linear relationship with the presence of CMBs, even in the full multivariate model. One might speculate that only relatively high intensities of PA protect against CMBs.

The association of PA with larger brain volume, better cognitive function, and lower risk of dementia in the general population, including the elderly, has already been established [11, 40]. Aerobic exercise training has been shown to be effective at reversing hippocampal volume loss in late adulthood, which is accompanied by improved memory function [41]. Progressive aerobic training has also been found to improve cognitive function in a randomized controlled trial [42]. In our study, RE and higher weekly PA were associated with larger nBV. Although regional volumes relevant for memory function were not available for the present analysis, we were able to show that RE and, by trend, also weekly PA were independently associated with better global cognitive performance. In a post hoc analysis, RE was associated with better cognitive performance in all age strata. Thus, PA might reduce brain atrophy and improve cognitive function in patients with AF [30].

Additionally, the risk of falls has to be considered, especially among elderly patients on oral anticoagulation. However, exercise programs have been shown to reduce falls in older people [43].

Accordingly, PA can also be seen as a preventive measure to reduce the risk of falls, although further studies are needed, especially on which type of PA is safe and most favorable in this regard in the elderly.

The amount of PA in our study population (median = 4479 MET-min/week) is somewhat lower than in the general Swiss population aged >65 years (mean = 5692 in people aged >65 years) [21]. However, this difference can be expected, as we included patients with heart disease.

Strengths and limitations

There are several strengths of this study. First, the sample size is large and consists of well-characterized patients with AF. As we have detailed data on patients' characteristics and medical history, we were able to adjust for several potential confounders. Second, bMRI scans were performed according to a standardized protocol and analyzed by trained neuroradiologists. Third, study personnel were trained to perform neurocognitive tests in a consistent way to ensure comparability and minimize performance bias. Fourth, the IPAQ is a well-validated questionnaire, allowing comparison with other studies and research data.

The most important limitation of the present analysis is its cross-sectional design, which does not allow establishing a causal relationship between PA and the outcomes measured. Prospective trials are needed to explore whether PA prevents vascular brain lesions and cognitive decline. There are far more males in our study population than females. Male sex is a known risk factor for AF [44]. Even when taking into consideration that more men than women live with cardiovascular disease [45], women are still underrepresented in cardiovascular research, possibly due to reduced willingness to participate, sociocultural factors, and lack of awareness on the part of investigators [46]. As we did not keep a screening log of subjects declining to participate in Swiss-AF, we cannot provide specific reasons for underrepresentation of women in our study.

Furthermore, the questionnaire was completed by the study patients without supervision. Examples were given for each PA level, but a wide range of individual interpretation is possible. Moreover, we cannot draw any conclusions as to the optimal quantity or intensity of PA, as the analysis of MET-min/week did not yield consistent linear effects, except on brain volume.

Finally, although we adjusted for several potential confounders, we cannot rule out residual confounding through nonmeasured factors or behaviors associated with a healthy lifestyle.

CONCLUSIONS

A majority of research in lifestyle interventions focuses on healthy older adults. The present study examined the potential importance of PA for brain health in patients with AF. The main conclusion is that the beneficial effects of PA on brain health may also be present

in patients with AF. The associations with a lower prevalence of ischemic brain infarcts and white matter disease, larger brain volume, and better neurocognitive performance might indicate a potential protective effect of PA, but confirmation in prospective studies is warranted. Pending further research, patients with AF can be encouraged to remain physically active.

FUNDING INFORMATION

The Swiss-AF study is supported by grants from the Swiss National Science Foundation (grant numbers 33CS30_148474, 33CS30_177520, 32473B_176178, and 32003B_197524), the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel, and the University of Basel.

CONFLICT OF INTEREST

T.R. has received research grants from the Goldschmidt-Jacobson Foundation, the Swiss National Science Foundation, the Swiss Heart Foundation, the European Union, the Professor Max Cloëtta Foundation, the Cardiovascular Research Foundation Basel, the University of Basel, and the University Hospital Basel, all outside of the presented work. He has received speaker/consulting honoraria or travel support from Abbott/SJM, AstraZeneca, Brahms, Bayer, Biosense Webster, Medtronic, Pfizer-BMS, and Roche, all outside of the presented work. He has received support for his institution's fellowship program (Inselspital Bern) from Biosense Webster, Biotronik, Medtronic, Abbott/SJM, and Boston Scientific, all outside of the presented work. N.R. has received a grant from the Swiss Heart Foundation. J.H.B. reports grants from the Swiss National Foundation of Science, the Swiss Heart Foundation, and Bayer, and lecture fees from Sanofi Aventis and Amgen, to the institution outside the submitted work. A.M. has received fellowship and training support from Biotronik, Boston Scientific, Medtronic, Abbott/St. Jude Medical, and Biosense Webster, and speaker honoraria from Biosense Webster, Medtronic, Abbott/St. Jude Medical, AstraZeneca, Daiichi Sankyo, Biotronik, and MicroPort, and is a consultant for Biosense Webster, Medtronic, and Abbott/St. Jude Medical. M.D. is an employee of the Medical Image Analysis Center (MIAC), has received speaker honoraria from Bayer Vital and Sanofi Genzyme, and is a consultant for Hovid Berhad and Roche Pharma, all outside of the presented work. J.W. is an employee of MIAC, has received funding from the EU (Horizon2020), Else-Kröner-Fresenius Foundation, and Novartis Foundation, and has received consultancy, steering committee, advisory board, and speaker honoraria from Actelion, Bayer, Biogen, Idorsia, Roche, Sanofi Genzyme, and Teva. D.C. has received speaker fees from BMS/Pfizer and consulting fees from Roche Diagnostics, both outside of the current work. M.K. reports personal fees from Bayer, Böhringer Ingelheim, Pfizer BMS, Daiichi Sankyo, Medtronic, Biotronik, Boston Scientific, Johnson & Johnson, and Roche, and grants from Bayer, Pfizer, Boston Scientific, BMS, Biotronik, and Daiichi Sankyo. S.O. has received a grant from the Swiss National Science Foundation. L.H.B. has received grants from the Swiss National Science Foundation (PBBSB-116873, 33CM30-124,119, 32003B-156,658, 32003B-197,524), the Swiss

Heart Foundation, and the University of Basel, an unrestricted research grant from AstraZeneca, consultancy or advisory board fees or speaker's honoraria from Amgen, Bayer, Bristol-Myers Squibb, and Claret Medical, and travel grants from AstraZeneca and Bayer. None of the other authors has any conflict of interest to disclose.

DATA AVAILABILITY STATEMENT

Data supporting the findings of this study and any data not published within this article are accessible in a public repository. On request, data are available from the corresponding author.

ORCID

Elena Herber  <https://orcid.org/0000-0001-8228-3646>

Tim Sinnecker  <https://orcid.org/0000-0003-1508-318X>

Stefan Osswald  <https://orcid.org/0000-0002-9240-6731>

REFERENCES

- Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. *Circ Res*. 2020;127:4-20.
- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. *Int J Stroke*. 2021;16:217-221.
- Mou L, Norby FL, Chen LY, et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (atherosclerosis risk in communities). *Circ Arrhythm Electrophysiol*. 2018;11:e006350.
- Berman JP, Norby FL, Mosley T, et al. Atrial fibrillation and brain magnetic resonance imaging abnormalities. *Stroke*. 2019;50:783-788.
- Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 2013;158:338-346.
- Conen D, Rodondi N, Müller A, et al. Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation. *J Am Coll Cardiol*. 2019;73:989-999.
- Chen LY, Lopez FL, Gottesman RF, et al. Atrial fibrillation and cognitive decline—the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. *Stroke*. 2014;45:2568-2574.
- Alber J, Alladi S, Bae HJ, et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities. *Alzheimers Dement (N Y)*. 2019;5:107-117.
- Soares-Miranda L, Siscovick DS, Psaty BM, Longstreth WT Jr, Mozaffarian D. Physical activity and risk of coronary heart disease and stroke in older adults: the cardiovascular health study. *Circulation*. 2016;133:147-155.
- Shaaban CE, Aizenstein HJ, Jorgensen DR, et al. Physical activity and cerebral small vein integrity in older adults. *Med Sci Sports Exerc*. 2019;51:1684-1691.
- Tan ZS, Spartano NL, Beiser AS, et al. Physical activity, brain volume, and dementia risk: the Framingham study. *J Gerontol A Biol Sci Med Sci*. 2017;72:789-795.
- Moroni F, Ammirati E, Rocca MA, Filippi M, Magnoni M, Camici PG. Cardiovascular disease and brain health: focus on white matter hyperintensities. *Int J Cardiol Heart Vasc*. 2018;19:63-69.
- Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. *JAMA*. 2009;302:627-637.
- de Bruijn RF, Schrijvers EM, de Groot KA, et al. The association between physical activity and dementia in an elderly population: the Rotterdam study. *Eur J Epidemiol*. 2013;28:277-283.
- Gu Y, Beato JM, Amarante E, et al. Assessment of leisure time physical activity and brain health in a multiethnic cohort of older adults. *JAMA Netw Open*. 2020;3:e2026506.
- Stephen R, Liu Y, Ngandu T, et al. Brain volumes and cortical thickness on MRI in the Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER). *Alzheimers Res Ther*. 2019;11:53.
- Venkatraman VK, Sanderson A, Cox KL, et al. Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. *Neurobiol Aging*. 2020;89:132-141.
- Sexton CE, Betts JF, Demnitz N, Dawes H, Ebmeier KP, Johansen-Berg H. A systematic review of MRI studies examining the relationship between physical fitness and activity and the white matter of the ageing brain. *Neuroimage*. 2016;131:81-90.
- Conen D, Rodondi N, Mueller A, et al. Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillation. *Swiss Med Wkly*. 2017;147:w14467.
- Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc*. 2003;35:1381-1395.
- Wanner M, Probst-Hensch N, Kriemler S, Meier F, Autenrieth C, Martin BW. Validation of the long international physical activity questionnaire: influence of age and language region. *Prev Med Rep*. 2016;3:250-256.
- Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc*. 2011;43:1334-1359.
- Schwendinger F, Wagner J, Infanger D, Schmidt-Trucksäss A, Knaier R. Methodological aspects for accelerometer-based assessment of physical activity in heart failure and health. *BMC Med Res Methodol*. 2021;21:251.
- Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-838.
- Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. *Neuroimage*. 2002;17:479-489.
- Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53:695-699.
- Tombaugh TN. Trail making test a and B: normative data stratified by age and education. *Arch Clin Neuropsychol*. 2004;19:203-214.
- Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. clinical and neuropsychological assessment of Alzheimer's disease. *Neurology*. 1989;39:1159-1165.
- Springer A, Monsch AU, Dutilh G, et al. A factor score reflecting cognitive functioning in patients from the Swiss atrial fibrillation cohort study (Swiss-AF). *PLoS One*. 2020;15:e0240167.
- Jackson PA, Pialoux V, Corbett D, et al. Promoting brain health through exercise and diet in older adults: a physiological perspective. *J Physiol*. 2016;594:4485-4498.
- Middleton LE, Corbett D, Brooks D, et al. Physical activity in the prevention of ischemic stroke and improvement of outcomes: a narrative review. *Neurosci Biobehav Rev*. 2013;37:133-137.
- Escudero-Martínez I, Mancha F, Vega-Salvatierra Á, et al. Mediterranean diet and physical activity protect from silent brain infarcts in a cohort of patients with atrial fibrillation. *J Stroke*. 2019;21:353-355.
- Wendel-Vos GC, Schuit AJ, Feskens EJ, et al. Physical activity and stroke. A meta-analysis of observational data. *Int J Epidemiol*. 2004;33:787-798.
- Aeschbacher S, Blum S, Meyre PB, et al. Blood pressure and brain lesions in patients with atrial fibrillation. *Hypertension*. 2021;77:662-671.

35. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam scan study. *Stroke*. 2003;34:1126-1129.
36. Landman TR, Thijssen DH, Tuladhar AM, De Leeuw FE. Relation between physical activity and cerebral small vessel disease: a nine-year prospective cohort study. *Int J Stroke*. 2021;16:962-971.
37. Bolandzadeh N, Tam R, Handy TC, et al. Resistance training and White matter lesion progression in older women: exploratory analysis of a 12-month randomized controlled trial. *J Am Geriatr Soc*. 2015;63:2052-2060.
38. Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. *Lancet Neurol*. 2018;17:539-547.
39. Vernooij MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam scan study. *Neurology*. 2008;70:1208-1214.
40. Erickson KI, Hillman C, Stillman CM, et al. Physical activity, cognition, and brain outcomes: a review of the 2018 physical activity guidelines. *Med Sci Sports Exerc*. 2019;51:1242-1251.
41. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. *Proc Natl Acad Sci USA*. 2011;108:3017-3022.
42. Liu-Ambrose T, Best JR, Davis JC, et al. Aerobic exercise and vascular cognitive impairment: a randomized controlled trial. *Neurology*. 2016;87:2082-2090.
43. Sherrington C, Fairhall NJ, Wallbank GK, et al. Exercise for preventing falls in older people living in the community. *Cochrane Database Syst Rev*. 2019;2019(1):CD012424.
44. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. *Circ Res*. 2017;120:1501-1517.
45. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. *Circulation*. 2011;124:2145-2154.
46. Tobb K. Underrepresentation of women in cardiovascular trials- it is time to shatter this glass ceiling. *Am Heart J Plus Cardiol Res Pract*. 2022;13:100109.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Herber E, Aeschbacher S, Coslovsky M, et al. Physical activity and brain health in patients with atrial fibrillation. *Eur J Neurol*. 2023;30:567-577. doi:[10.1111/ene.15660](https://doi.org/10.1111/ene.15660)